Save the date for this annual Women’s Day themed panel talk and workshop followed by a networking lunch at SBC!
11.45: arrivals, coffee and taking seats
12.00-12.45: talks and panel:
Stevenage Bioscience Catalyst (SBC) is seeking an experienced Leasing Asset Manager to join its senior team on a part-time basis, working between 22.5 and 30 hours per week.
Reporting to the Finance Director, this role sits at the heart of SBC’s operations and will play a key role in managing and optimising the campus’s laboratory and office portfolio, supporting tenant growth, and helping shape the continued evolution of one of the UK’s most successful life science campuses.
About Stevenage Bioscience Catalyst
Royston, 3 February 2026.
Bring more to life.
Are you ready to accelerate your potential and make a real difference within life sciences, diagnostics and biotechnology?
At Abcam, one of Danaher’s 15+ operating companies, our work saves lives—and we’re all united by a shared commitment to innovate for tangible impact.
You’ll thrive in a culture of belonging where you and your unique viewpoint matter. And by harnessing Danaher’s system of continuous improvement, you help turn ideas into impact – innovating at the speed of life.
Progress happens together
About the Team
The AlphaFold Database (AFDB) is a key resource developed by Google DeepMind and EMBL-EBI, empowering researchers to harness the power of AI-predicted protein structures. It is located within the Protein Data Bank in Europe (PDBe) team, which develops and maintains structural biology databases used by researchers worldwide.
At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success.
This event will show you how a structured AI approach across your data, CRM and revenue operations can enable scalable, compliant growth for all size businesses.
What you will learn:
At AstraZeneca, we aim to revolutionise antibody discovery by significantly reducing the time to reach a clinical candidate using world-class technology and advanced data & AI capabilities. The Biologics Discovery Platform Product Lead will build a multi-quarter product roadmap and strategy to deliver an excellent science user experience, partnering with R&D product owners and cross-functional teams that work in the earliest stages of Biologics discovery.
About Maxion
Maxion Therapeutics is a pioneering biotechnology company dedicated to developing groundbreaking biologic medicines for diseases with unmet needs, driven by ion channel and GPCR dysfunction. Our innovative KnotBody® technology empowers us to create potent, selective, and durable antibody therapeutics. This technology merges millions of years of cysteine-rich mini-protein ('Knottin') evolution with cutting-edge antibody engineering, addressing pivotal challenges in ion channel/GPCR drug discovery.
The Insights team is LifeArc’s central resource for analysing scientific, competitive and IP landscapes to support strategy, project selection and portfolio decisions. The team works closely with LifeArc Ventures and our Translational Challenges to analyse the potential of translational life science opportunities, informing decision making and ensuring LifeArc achieves maximum patient impact.